Author
Van Andel Institute
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
Lauren E. McGee, Jamie L. Grit, Curt J. Essenburg…·Matthew R. Steensma
This study identifies YAP signaling as a driver of resistance to MEK and AKT inhibitors in NF1-related MPNSTs using preclinical models and spatial transcriptomics.
Anna Shemorry, Willem den Besten, Melinda M. Mulvihill…·Ingrid E. Wertz
This study evaluates bifunctional ER degraders with different ubiquitin ligase ligands, finding that pan-IAP antagonists enhance ER degradation and induce TNF-dependent cell death more effectively than existing therapies.
Rachel J. House, Elizabeth A. Tovar, Luke N. Redlon…·Matthew R. Steensma
This study investigates how NF1 deficiency affects metabolic reprogramming in ER+ breast cancer and identifies potential therapeutic synergies between metabolic and targeted inhibitors.
Matthew G. Pridgeon, Elizabeth A. Tovar, Curt J. Essenburg…·Matthew R. Steensma
This study shows that P53 status modulates the response to MET and MEK inhibition in NF1-related MPNSTs, with P53 wild-type tumors showing greater suppression of RAS/MAPK and PI3K/AKT activation.
Jacqueline D. Peacock, Matthew G. Pridgeon, Elizabeth A. Tovar…·Matthew R. Steensma
This study identifies early MET amplification in NF1-related MPNST progression and shows MET inhibition effectively targets these tumors.